Hjem
Line Bjørges bilde

Line Bjørge

Professor
  • E-postLine.Bjorge@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) 2021. Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. Cancers. 1-18.
  • Vis forfatter(e) 2021. Decidual and placental NOD1 is associated with inflammation in normal and preeclamptic pregnancies . Placenta. 23-31.
  • Vis forfatter(e) 2020. Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers. 1-18.
  • Vis forfatter(e) 2020. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • Vis forfatter(e) 2020. Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential. Experimental Cell Research. 1-9.
  • Vis forfatter(e) 2020. DNA methylation signatures to predict the cervicovaginal microbiome status. Clinical Epigenetics.
  • Vis forfatter(e) 2020. Cholesterol crystals and NLRP3 mediated inflammation in the uterine wall decidua in normal and preeclamptic pregnancies. Frontiers in Immunology. 1-12.
  • Vis forfatter(e) 2020. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model . EBioMedicine. 1-12.
  • Vis forfatter(e) 2020. CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine. 1-13.
  • Vis forfatter(e) 2019. Shared heritability and functional enrichment across six solid cancers. Nature Communications. 1-23.
  • Vis forfatter(e) 2019. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. The Lancet Oncology. 1409-1419.
  • Vis forfatter(e) 2019. Metabolomics identifies placental dysfunction and confirms Flt-1 (FMS-like tyrosine kinase receptor 1) biomarker specificity. Hypertension. 1136-1143.
  • Vis forfatter(e) 2019. Influence of p53 isoform expression on survival in high-grade serous ovarian cancers. Scientific Reports. 1-11.
  • Vis forfatter(e) 2019. Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk. Cancer Research. 505-517.
  • Vis forfatter(e) 2019. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. International Journal of Cancer. 1-10.
  • Vis forfatter(e) 2019. Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American women. Cancer Medicine. 2503-2513.
  • Vis forfatter(e) 2019. Concentration of fibrin monomer in pregnancy and during the postpartum period. Annals of Clinical Biochemistry. 1-9.
  • Vis forfatter(e) 2019. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. The Lancet Oncology. 1171-1182.
  • Vis forfatter(e) 2019. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemotherapy and Pharmacology. 791-798.
  • Vis forfatter(e) 2018. rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. International Journal of Molecular Sciences. 1-13.
  • Vis forfatter(e) 2018. Within-subject biological variation of activated partial thromboplastin time, prothrombin time, fibrinogen, factor VIII and von Willebrand factor in pregnant women. Clinical Chemistry and Laboratory Medicine. 1-12.
  • Vis forfatter(e) 2018. White blood cell BRCA1 promoter methylation status and ovarian cancer risk. Annals of Internal Medicine. 326-334.
  • Vis forfatter(e) 2018. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLOS ONE. 1-13.
  • Vis forfatter(e) 2018. Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. Journal of Magnetic Resonance Imaging. 1637-1647.
  • Vis forfatter(e) 2018. Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiologica. 1010-1017.
  • Vis forfatter(e) 2018. Placental inflammation in pre-eclampsia by Nod-like receptor protein (NLRP)3 inflammasome activation in trophoblasts. Clinical and Experimental Immunology. 84-94.
  • Vis forfatter(e) 2018. Placental inflammation by HMGB1 activation of TLR4 at the syncytium. Placenta. 53-61.
  • Vis forfatter(e) 2018. High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 1-10.
  • Vis forfatter(e) 2018. Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG: An International Journal of Obstetrics and Gynaecology. 1695-1703.
  • Vis forfatter(e) 2018. Adult height is associated with increased risk of ovarian cancer: A Mendelian randomisation study. British Journal of Cancer. 1123-1129.
  • Vis forfatter(e) 2018. A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk. Cancer Research. 5419-5430.
  • Vis forfatter(e) 2017. Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. OncoTarget. 106989-107001.
  • Vis forfatter(e) 2017. Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • Vis forfatter(e) 2017. Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study. PLOS ONE. 1-12.
  • Vis forfatter(e) 2017. In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica. 497-505.
  • Vis forfatter(e) 2017. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics. 680-691.
  • Vis forfatter(e) 2017. Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. British Journal of Cancer. 840-847.
  • Vis forfatter(e) 2017. C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease. PLOS ONE. 1-12.
  • Vis forfatter(e) 2017. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. OncoTarget. 64670-64684.
  • Vis forfatter(e) 2017. A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway. Acta Obstetricia et Gynecologica Scandinavica. 1162-1169.
  • Vis forfatter(e) 2016. Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. OncoTarget. 69844-69856.
  • Vis forfatter(e) 2016. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • Vis forfatter(e) 2016. The antihypertensive MTHFR gene polymorphism rs17367504-G is a possible novel protective locus for preeclampsia. Journal of Hypertension. 132-139.
  • Vis forfatter(e) 2016. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLOS ONE.
  • Vis forfatter(e) 2016. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology. 78-89.
  • Vis forfatter(e) 2016. PALB2, CHEK2 and ATM rare variants and cancer risk: Data from COGS. Journal of Medical Genetics. 800-811.
  • Vis forfatter(e) 2016. Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: Results from a large-scale collaboration. OncoTarget. 72381-72394.
  • Vis forfatter(e) 2016. Implementing medical abortion with mifepristone and misoprostol in Norway 1998-2013. International Journal of Epidemiology.
  • Vis forfatter(e) 2016. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications.
  • Vis forfatter(e) 2016. Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer. Cancer Epidemiology, Biomarkers and Prevention. 61-67.
  • Vis forfatter(e) 2016. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute. 1-10.
  • Vis forfatter(e) 2016. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. OncoTarget. 69097-69110.
  • Vis forfatter(e) 2016. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics. 741-756.
  • Vis forfatter(e) 2016. Adverse pregnancy outcomes after treatment for cervical intraepithelial neoplasia. Obstetrics and Gynecology. 1265-1273.
  • Vis forfatter(e) 2016. Adult body-mass index and ovarian cancer risk by subtype: A Mendelian randomization study. International Journal of Epidemiology. 884-895.
  • Vis forfatter(e) 2015. Tumour apparent diffusion coefficient is associated with depth of myometrial invasion and is negatively correlated to tumour volume in endometrial carcinomas. Clinical Radiology. 487-494.
  • Vis forfatter(e) 2015. The Norwegian preeclampsia family cohort study: a new resource for investigating genetic aspects and heritability of preeclampsia and related phenotypes. BMC Pregnancy and Childbirth. 1-12.
  • Vis forfatter(e) 2015. Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics. 5955-5964.
  • Vis forfatter(e) 2015. Refined phenotyping identifies links between preeclampsia and related diseases in a Norwegian preeclampsia family cohort. Journal of Hypertension. 2294-2302.
  • Vis forfatter(e) 2015. Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas. International Journal of Gynecological Cancer. 459-466.
  • Vis forfatter(e) 2015. Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 1574-1584.
  • Vis forfatter(e) 2015. Metabolic tumor volume on 18F-FDG PET/CT improves preoperative identification of high-risk endometrial carcinoma patients. Journal of Nuclear Medicine. 1191-1198.
  • Vis forfatter(e) 2015. Metabolic profiles of placenta in preeclampsia using HR-MAS MRS metabolomics. Placenta. 1455-1462.
  • Vis forfatter(e) 2015. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics. 164-171.
  • Vis forfatter(e) 2015. Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics. 888-897.
  • Vis forfatter(e) 2015. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology. 542-548.
  • Vis forfatter(e) 2015. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology. 689-697.
  • Vis forfatter(e) 2015. Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLOS ONE.
  • Vis forfatter(e) 2015. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications.
  • Vis forfatter(e) 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • Vis forfatter(e) 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • Vis forfatter(e) 2014. Medical abortion with mifepristone and home administration of misoprostol up to 63 days' gestation. Acta Obstetricia et Gynecologica Scandinavica. 647-653.
  • Vis forfatter(e) 2014. Landscape of genomic alterations in cervical carcinomas. Nature. 371-375.
  • Vis forfatter(e) 2014. Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. British Journal of Cancer. 107-114.
  • Vis forfatter(e) 2014. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics. 481-497.
  • Vis forfatter(e) 2014. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLOS ONE.
  • Vis forfatter(e) 2014. Consortium analysis of diet-gene interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition & Food Research. 2023-2035.
  • Vis forfatter(e) 2013. Validity of the diagnosis of pre-eclampsia in the Medical Birth Registry of Norway. Acta Obstetricia et Gynecologica Scandinavica. 943-950.
  • Vis forfatter(e) 2013. Validity of pre-eclampsia diagnosis in Medical Birth Registry of Norway. Acta Obstetricia et Gynecologica Scandinavica. 243-950.
  • Vis forfatter(e) 2013. Menstrual Cycle and Respiratory Symptoms in a General Nordic-Baltic Population. American Journal of Respiratory and Critical Care Medicine. 366-373.
  • Vis forfatter(e) 2013. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. European Radiology. 2916-2925.
  • Vis forfatter(e) 2012. Pregnancy outcomes after paternal radiofrequency field exposure aboard fast patrol boats. Journal of Occupational and Environmental Medicine. 431-438.
  • Vis forfatter(e) 2012. No effects of MRI scan on male reproduction hormones. Reproductive Toxicology. 133-139.
  • Vis forfatter(e) 2012. Er det mulig å få pålitelig kunnskap om psykiske senvirkninger etter provosert abort? Tidsskrift for Den norske legeforening. 1450-1452.
  • Vis forfatter(e) 2011. Increased endoplasmic reticulum stress in decidual tissue from pregnancies complicated by fetal growth restriction with and without pre-eclampsia. Placenta. 823-829.
  • Vis forfatter(e) 2011. Identification of ACOX2 as a shared genetic risk factor for preeclampsia and cardiovascular disease. European Journal of Human Genetics. 796-800.
  • Vis forfatter(e) 2011. A transcriptional profile of the decidua in preeclampsia. American Journal of Obstetrics and Gynecology. 84, e1-84, e27.
  • Vis forfatter(e) 2010. STOX2 but not STOX1 is differently expressed in preeclampstic decidua from Norwegian women: data from the Second Nord-Trondelag Health Study. Molecular human reproduction. 960-968.
  • Vis forfatter(e) 2010. Medical Abortion at 63 to 90 Days of Gestation. Obstetrics and Gynecology. 962-968.
  • Vis forfatter(e) 2010. Matrix Metalloproteinase 1 in Pre-eclampsia and Fetal Growth Restriction: Reduced Gene Expression in Decidual Tissue and Protein Expression in Extravillous Trophoblasts. Placenta. 615-620.
  • Vis forfatter(e) 2009. Oral contraception, body mass index, and asthma: A cross-sectional Nordic-Baltic population survey. Journal of Allergy and Clinical Immunology. 391-397.
  • Vis forfatter(e) 2008. Whole-genome microarray and targeted placental analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PIGF) from pre-eclamptic and small-for-gegstational-age pregnancies. Journal of Maternal-Fetal & Neonatal Medicine. 158-165.
  • Vis forfatter(e) 2006. Placental expression of glycophosphatidylinositol (GPI)-anchored proteins in paroxysmal nocturnal haemoglobinuria. Scandinavian Journal of Immunology.
  • Vis forfatter(e) 2006. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy. Scandinavian Journal of Immunology. 355-364.
  • Vis forfatter(e) 2006. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy. Scandinavian Journal of Immunology. 355-364.
  • Vis forfatter(e) 2006. Cardiopulmonary distress during obstetrical anaesthesia: attempts to diagnose amniotic fluid embolism in a case series of suspected allergic anaphylaxis. Acta Anaesthesiologica Scandinavica. 324-330.
  • Vis forfatter(e) 2005. Ascitic complement system in ovarian cancer. British Journal of Cancer. 895-905.
Faglig foredrag
  • Vis forfatter(e) 2019. The NLRP3 inflammasome expression by maternal and fetal cells in the uterine wall and association with preeclampsia development. .
  • Vis forfatter(e) 2019. NLRP3 inflammasome expression by maternal and fetal cells in decidua and its association with preeclampsia .
  • Vis forfatter(e) 2019. Divergent regulation of decidual oxidative stress response in preeclampsia with and without fetal growth restriction.
  • Vis forfatter(e) 2017. Inflammation in preeclampsia by NOD-like receptor protein (NLRP)3 inflammasome activation in trophoblasts.
  • Vis forfatter(e) 2017. An inflammatory role for NOD1 in decidua and placenta of normal and preeclamptic pregnancies.
  • Vis forfatter(e) 2014. Inflammation in normal and preeclamptic pregnancies.
Vitenskapelig foredrag
  • Vis forfatter(e) 2021. The link between inflammatory and vascular pathology and sFlt-1 expression at the maternal-fetal interface in preeclampsia.
  • Vis forfatter(e) 2021. Systemic immunological perturbations and placental pathology in preeclampsia.
  • Vis forfatter(e) 2018. Decidual inflammation in normal and preeclamptic pregnancies.
  • Vis forfatter(e) 2016. Decidual Nrf2-mediated oxidative stress response in preeclampsia and fetal growth restriction.
  • Vis forfatter(e) 2015. The inflammatory role of HMGB1 in preeclampsia.
  • Vis forfatter(e) 2013. Preeclampsia and cardiovascular disease - shared causative genetic mechanisms?
  • Vis forfatter(e) 2013. Arvelighet av kardiovaskulær sykdom i en familiekohort med økt forekomst av preeklampsi.
  • Vis forfatter(e) 2013. A preeclampsia genome-wide linkage scan in Norwegian families.
  • Vis forfatter(e) 2011. MEDICAL ABORTION WITH HOME ADMINISTRATION OF MISOPROSTOL UP TO 63 DAYS GESTATION.
  • Vis forfatter(e) 2010. Norway: In transition from surgical to medical termination.
  • Vis forfatter(e) 2010. Endoplasmic reticulum stress in decidual tissue from pregnancies complicated by pre-eclampsia.
  • Vis forfatter(e) 2008. Women's choices: Why do they opt for medical abortion?
Doktorgradsavhandling
  • Vis forfatter(e) 2020. Biomarkers and preclinical models for more precise diagnosis and personalized treatment of oral and vulva carcinomas - Study on human samples and experimental models.
  • Vis forfatter(e) 2019. Rethinking Gynecological High- Grade Serous Carcinoma. Portraying the p53 isoform landscape and development of a new preclinical for optical imaging in xenograft models.
  • Vis forfatter(e) 1996. Complement regulatory proteins in malignancies. -.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) 2007. Immunologi og reproduksjon. 6 sider.
Sammendrag/abstract
  • Vis forfatter(e) 2021. The link between inflammatory and vascular pathology and sFlt-1 expression at the maternal-fetal interface in preeclampsia. Placenta. e13-e14.
  • Vis forfatter(e) 2021. Systemic immunological perturbations and placental pathology in preeclampsia. Placenta. e18-e19.
  • Vis forfatter(e) 2019. Toll-like receptor 3 expression and activation at the maternal-fetal interface in pregnancy . Clinical medicine (London).
  • Vis forfatter(e) 2019. Toll-Like Receptor-3 expression by maternal and fetal cells at the maternal-fetal interface is associated with development of preeclampsia. Pregnancy Hypertension. S15.
  • Vis forfatter(e) 2019. The NLRP3 inflammasome expression by maternal and fetal cells in the uterine wall and association with preeclampsia development. Placenta. e15.
  • Vis forfatter(e) 2019. Metabolomics identifies placental dysfunction and confirms Flt-1 biomarker specificity. Pregnancy Hypertension. S5.
  • Vis forfatter(e) 2019. Divergent regulation of decidual oxidative stress response in preeclampsia with and without fetal growth restriction. Pregnancy Hypertension. S21.
  • Vis forfatter(e) 2018. Decidual inflammation in normal and preeclamptic pregnancies. Pregnancy Hypertension. S33-S34.
  • Vis forfatter(e) 2017. No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers and Prevention. 420-424.
  • Vis forfatter(e) 2017. Inflammation in preeclampsia by NOD-like receptor protein (NLRP)3 inflammasome activation in trophoblasts. Pregnancy Hypertension. 21.
  • Vis forfatter(e) 2017. An inflammatory role for TLR3 in decidua and placenta of normal and preeclamptic pregnancies. Placenta. 278.
  • Vis forfatter(e) 2017. An inflammatory role for NOD1 in decidua and placenta of normal and preeclamptic pregnancies. Placenta. 235.
  • Vis forfatter(e) 2016. NLRP3 inflammasome expression and activation at the maternal-fetal interface in preeclamptic and healthy pregnancies. Placenta. 88-88.
  • Vis forfatter(e) 2015. The inflammatory role of HMGB1 in preeclampsia. Pregnancy Hypertension. 229.
  • Vis forfatter(e) 2015. Identifying a novel link between preeclampsia and chronic hypertension in the MTHFR gene using the population based Norwegian HUNT Study. Pregnancy Hypertension. 243-244.
  • Vis forfatter(e) 2015. A genetic connection between preeclampsia and chronic hypertension in Norwegian families. Pregnancy Hypertension. 138-139.
  • Vis forfatter(e) 2013. PANOBINOSTAT / CARBOPLATIN DELAY POSTSURGICAL RELAPSE OF OVARIAN CARCINOMA IN AN ORTHOTOPIC MOUSE MODEL. International Journal of Gynecological Cancer. 1 sider.
  • Vis forfatter(e) 2013. Arvelighet av kardiovaskulær sykdom i en familiekohort med økt forekomst av preeklampsi. Gynekologen. 43-44.
  • Vis forfatter(e) 2013. A preeclampsia genome-wide linkage scan in Norwegian families. Pregnancy Hypertension. 64.
  • Vis forfatter(e) 2012. Venøs trombose i svangerskapet: Internasjonale retningslinjer blir norske. Gynekologen. 43.
  • Vis forfatter(e) 2012. Trender i bruken av medikamentell abort i Noreg. Gynekologen.
  • Vis forfatter(e) 2012. Medical abortion with home administration of misoprostol up to 63 days gestation. Acta Obstetricia et Gynecologica Scandinavica. 33-34.
  • Vis forfatter(e) 2012. Medical abortion at 9-12 weeks. Acta Obstetricia et Gynecologica Scandinavica. 49-49.
  • Vis forfatter(e) 2012. INVESTIGATING GENETIC PREDISPOSITION AND CLINICAL OCCURRENCE OF PREECLAMPSIA AND CARDIOVASCULAR DISEASE THROUGH A FAMILY-BASED DESIGN. Placenta. A82-A82.
  • Vis forfatter(e) 2012. HPV-vaksinasjon – er kunnskapsnivået hos norske medisinetstudenter og allmennleger tilstrekkelig høyt? Gynekologen. 43.
  • Vis forfatter(e) 2012. Establishment of a bioluminescence orthotopic mouse model of ovarian carcinoma: Analysis of tumor growth and response to therapy. Acta Obstetricia et Gynecologica Scandinavica. 16-17.
  • Vis forfatter(e) 2012. A population and family based study design to investigate genetic predisposition to preeclampsia and cardiovascular disease. The Norwegian Preeclampsia Family Study. Acta Obstetricia et Gynecologica Scandinavica. 135-136.
  • Vis forfatter(e) 2011. Establishment of a Norwegian Preeclampsia Family Biobank. Placenta. A85-A85.
  • Vis forfatter(e) 2011. Endoplasmic reticulum stress in decidual tissue from pregnancies complicated by pre-eclampsia and fetal growth restriction. Placenta.
  • Vis forfatter(e) 2010. Endoplasmatic reticulum stress in decidual tissue from pregnancies complicated with preeclampsia. Hypertension in Pregnancy.
  • Vis forfatter(e) 2010. Classification of pre-eclamptic pregnancies in health registries. An evaluation of criteria selected and pregnancies included in the Medical Birth Registry of Norway. Hypertension in Pregnancy.
Poster
  • Vis forfatter(e) 2019. What you should know about tumor reductive surgery in advanced ovarian cancer – Clinical recommendations from a patient perspective.
  • Vis forfatter(e) 2019. Toll-Like Receptor-3 expression by maternal and fetal cells at the maternal-fetal interface is associated with development of preeclampsia .
  • Vis forfatter(e) 2019. Toll-Like Receptor-3 expression by maternal and fetal cells at the maternal-fetal interface is associated with development of preeclampsia.
  • Vis forfatter(e) 2019. Metabolomics identifies placental dysfunction and confirms Flt-1 biomarker specificity.
  • Vis forfatter(e) 2019. EP889 improved cytoreduction of ovarian cancer using CD24 targeted fluorescence image guided surgery in a preclinical murine model.
  • Vis forfatter(e) 2018. TLR3 expression and activation at the maternal-fetal interface in pregnancy.
  • Vis forfatter(e) 2018. Inflammation at the uterine wall lining in pregnancy.
  • Vis forfatter(e) 2017. Engraftement optimization, charaterization and tumor spread tracking by preclinical imaging in ovarian cancer patiant.
  • Vis forfatter(e) 2017. An inflammatory role for TLR3 in decidua and placenta of normal and preeclamptic pregnancies.
  • Vis forfatter(e) 2016. Toll-like receptor 3 expression and activation at the maternal-fetal interface in pregnancy.
  • Vis forfatter(e) 2016. Nrf2-mediated oxidative stress response at the maternal-fetal interface in preeclampsia and fetal growth restriction.
  • Vis forfatter(e) 2016. NLRP3 inflammasome expression and activation at the maternal-fetal interface in preeclamptic and healthy pregnancies.
  • Vis forfatter(e) 2015. The inflammatory role of HMGB1 in preeclamptic and normal pregnancies.
  • Vis forfatter(e) 2015. The NLRP3 inflammasome in placentas from preeclamptic and healthy pregnancies.
  • Vis forfatter(e) 2015. Metabolic profiles of placenta in preeclampsia using HR-MAS MRS metabolomics.
  • Vis forfatter(e) 2014. Heritability of cardiovascular diseases in a preeclampsia family cohort.
  • Vis forfatter(e) 2014. A genetic connection between preeclampsia and chronic hypertension in Norwegian families.
  • Vis forfatter(e) 2013. Panobinostat / carboplatin delay postsurgical relapse of ovarian carcinomas in an orthotopic mouse model.
  • Vis forfatter(e) 2013. Histone deacetylase inhibisjon i kombinasjon med platinum i en klinisk relevant ortotopisk musemodel for ovarialcancer.
  • Vis forfatter(e) 2013. Heritability of cardiovascular diseases in a preeclampsia family cohort.
  • Vis forfatter(e) 2012. A family based cohort study design to investigate genetic predisposition to preeclampsia and cardiovascular disease. The Norwegian Preeclampsia Family Study.
  • Vis forfatter(e) 2011. Establishment of a Norwegian Preeclampsia Family Biobank.
  • Vis forfatter(e) 2011. Endoplasmic reticulum stress in decidual tissue from pregnancies complicated by pre-eclampsia and fetal growth restriction.
  • Vis forfatter(e) 2010. Medical abortion between 9 and 12 weeks gestation. Experiences from a nursing perspective. .
  • Vis forfatter(e) 2010. Classification of pre-eclamptic pregnancies in health registries. An evaluation of criteria selected and pregnancies included in the Medical Birth Registry of Norway.
  • Vis forfatter(e) 2010. Biobanking of tissue and blood from pregnancies.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) 2020. The emerging role of cd24 in cancer theranostics—a novel target for fluorescence image-guided surgery in ovarian cancer and beyond. Journal of Personalized Medicine. 1-18.
  • Vis forfatter(e) 2020. TLR3 expression by maternal and fetal cells at the maternal-fetal interface in normal and preeclamptic pregnancies. Journal of Leukocyte Biology. 1-11.
  • Vis forfatter(e) 2018. Epigenome-based cancer risk prediction: Rationale, opportunities and challenges. Nature Reviews Clinical Oncology. 292-309.
  • Vis forfatter(e) 2016. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology. 386-401.
  • Vis forfatter(e) 2012. Respiratory health in women: from menarche to menopause. Expert Review of Respiratory Medicine. 187-202.
Fagartikkel
  • Vis forfatter(e) 2014. Antikoagulasjon ved venøs trombose i svangerskapet. Tidsskrift for Den norske legeforening. 926-926.

Se fullstendig oversikt over publikasjoner i CRIStin.